SAN CARLOS, Calif., Aug. 22, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has now processed more than two million Panorama® ...

Natera announced plans to launch Panorama, a non-invasive prenatal screening test for the detection of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), and ...

TAMPA (FOX 13) - Every mother wants their newborn to be healthy, but not every pregnancy is risk-free. There is a new prenatal test helping to find abnormalities as early as nine weeks into pregnancy.

A new blood test is 99 percent more accurate than most pregnancy genetic test, and is an option that doesn't come with a risk of miscarriage. While genetic testing isn't always required during ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--Natera, a leading innovator in prenatal genetic testing, today announced the expansion of the Panorama™ non-invasive prenatal test (NIPT) to screen for five ...

AUSTIN, Texas, Aug. 10, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced earlier today at the Canaccord Genuity 42nd Annual Growth Conference in ...

SAN CARLOS, CALIFORNIA and TORONTO, ONTARIO--(Marketwired - Sep 11, 2013) - Natera, a leading innovator in prenatal genetic testing, and LifeLabs Medical Laboratory Services (LifeLabs), a Canadian ...

MedGenome, a provider of genomic solutions for personalized healthcare in India, and Natera, a global leader in non-invasive genetic testing, have entered into an exclusive agreement to bring ...

Natera announced Tuesday that it was ending the Panorama distribution agreement Natera said, under the agreement, BioReference was not to disparage the Natera test BioReference’s brochures promoting a ...